MedTrace Logo

The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment

NCT06039137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 395

Last updated 2024-09-25

No results posted yet for this study

Summary

In this study the effect of substituting clemastine IV to cetirizine PO on the occurence of hypersensitivity reactions during paclitaxel chemotherapy will be investigated.

Conditions

Interventions

DRUG

Cetirizine

Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine

DRUG

Clemastine IV

Subjects were treated with paclitaxel premedication containing clemastine 2 mg IV

Sponsors & Collaborators

Principal Investigators

  • Roelof van Leeuwen, PharmD, PhD · Erasmus Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-04-27
Completion
2023-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06039137 on ClinicalTrials.gov